SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control... Show more
SenesTech, a developer of fertility-control products for managing rodent populations, sits at a pivotal point in its growth story. The company has been shifting its e-commerce operations in-house while expanding a multi-channel strategy spanning e-commerce, retail, pest management professionals, municipalities, and agriculture. Recent quarters delivered record revenue and record gross margins, but the stock remains highly volatile and the company is still not profitable. The third-quarter 2026 report will test whether the e-commerce momentum and margin gains are durable, and whether management's push toward breakeven remains on track under new leadership following the appointment of a new CEO in mid-2026.
Analyst consensus for the third quarter of 2026 calls for revenue of approximately $694,500, which is roughly flat compared with the $690,000 reported in the third quarter of 2025. The consensus net loss per share is about $0.38, wider than the $0.28 loss reported a year earlier, partly reflecting a larger share count from prior equity raises.
SenesTech's most recent results provide important context. In the second quarter of 2026, the company reported a record $770,000 in revenue, up 23% year over year, and a record 73.6% gross margin. E-commerce revenue surged 206% year over year to $511,000, while subscription revenue jumped 142% to $104,000. Notably, the stock still fell about 23% after-hours following that report despite the beat, underscoring how sensitive this small-cap name is to any perceived shortfall in growth or clarity on profitability.
Key metrics investors will focus on this quarter include gross margin, e-commerce and subscription revenue, operating expenses, and cash burn.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following small-cap names like SenesTech, it offers a structured way to evaluate opportunities across sectors and identify signals worth a closer look.
SenesTech is a micro-cap stock, and its shares have historically shown outsized moves around earnings. The 23% after-hours decline following the second-quarter 2026 report, despite record results, illustrates that investors are weighing the company's path to profitability as much as its top-line growth. Heading into the third-quarter release, sentiment will likely hinge on whether the e-commerce transition continues to deliver, whether subscription-based recurring revenue keeps accelerating, and whether operating expenses stay disciplined. A wider-than-expected loss, slower revenue, or any signal of additional share dilution could weigh on the stock, while sustained margin gains and revenue upside could support a more favorable reaction.
Several factors will shape SenesTech's trajectory beyond this earnings event. The first is the transition of Amazon sales to in-house management. Early data from April 2026 showed e-commerce sales rising sharply year over year, and investors will want confirmation that the company can sustain that momentum without sacrificing profitability.
A second area to watch is recurring revenue. Subscription sales have been growing at a rapid clip, and a larger, more predictable revenue base would meaningfully de-risk the business model. Management has positioned direct-to-consumer and subscription channels as strategic priorities, so commentary on subscriber counts will matter.
Third, the agricultural and municipal opportunities represent potentially transformational but less predictable catalysts. A 400-acre Texas deployment reportedly showed an estimated 80% reduction in rodent activity, and expanded municipal programs in cities such as New York and Chicago continue to develop. International distribution agreements in markets like Bermuda, the U.S. Virgin Islands, and Belize add optionality.
Finally, investors should monitor the balance sheet. With roughly $5.1 million in cash at the end of the second quarter of 2026 and management indicating a runway into 2027, the rate of cash burn and any reliance on at-the-market (ATM) equity offerings will be closely watched, as dilution remains a key risk for shareholders.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a biotech platform and research company
Industry ChemicalsSpecialty